Epstein–Barr virus (EBV) is a ubiquitous herpesvirus that typically causes asymptomatic infection but can promote B lymphoid tumors in the immune suppressed. In vitro, EBV infection of primary B cells stimulates glycolysis during immortalization into lymphoblastoid cell lines (LCLs). Lactate export during glycolysis is crucial for continued proliferation of many cancer cells—part of a phenomenon known as the “Warburg effect”— and is mediated by monocarboxylate transporters (MCTs). However, the role of MCTs has yet to be studied in EBV-associated malignancies, which display Warburg-like metabolism in vitro. Here, we show that EBV infection of B lymphocytes directly promotes temporal induction of MCT1 and MCT4 through the viral proteins EBNA2 and LMP1, respectively. Functionally, MCT1 was required for early B cell proliferation, and MCT4 up-regulation promoted acquired resistance to MCT1 antagonism in LCLs. However, dual MCT1/4 inhibition led to LCL growth arrest and lactate buildup. Metabolic profiling in LCLs revealed significantly reduced oxygen consumption rates (OCRs) and NAD+/NADH ratios, contrary to previous observations of increased OCR and unaltered NAD+/NADH ratios in MCT1/4-inhibited cancer cells. Furthermore, U-13C6–glucose labeling of MCT1/4-inhibited LCLs revealed depleted glutathione pools that correlated with elevated reactive oxygen species. Finally, we found that dual MCT1/4 inhibition also sensitized LCLs to killing by the electron transport chain complex I inhibitors phenformin and metformin. These findings were extended to viral lymphomas associated with EBV and the related gammaherpesvirus KSHV, pointing at a therapeutic approach for targeting both viral lymphomas. Significance Epstein–Barr virus (EBV) infects virtually every human by adulthood with limited symptoms. However, in the context of immune suppression, EBV can cause lymphomas. EBV-associated lymphomas have poor prognoses and limited treatment options, highlighting a need to better understand EBV-mediated tumorigenesis. One common feature of viral replication and cancer is dysregulation of metabolism. Indeed, EBV dramatically reprograms host cell metabolism, up-regulating both oxidative phosphorylation and glycolysis. In this report, we identify metabolic vulnerabilities of EBV-infected primary human B cells, EBV-positive lymphomas, and lymphomas caused by the related oncogenic herpesvirus, KSHV. Pharmacological inhibition of lactate export suppressed these lymphomas and rendered them hypersensitive to metformin and phenformin. These findings together with our mechanistic studies outline a therapeutic strategy for viral lymphomas.